HC Wainwright Has Bullish Forecast for AURA FY2024 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Analysts at HC Wainwright boosted their FY2024 EPS estimates for Aura Biosciences in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($1.69) for the year, up from their previous forecast of ($1.71). HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for Aura Biosciences' Q4 2024 earnings at ($0.45) EPS, FY2025 earnings at ($1.94) EPS and FY2026 earnings at ($2.06) EPS.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02.

Other research analysts have also issued reports about the stock. JMP Securities raised their target price on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a "market outperform" rating in a research note on Friday, September 13th. Evercore ISI upgraded Aura Biosciences to a "strong-buy" rating in a research note on Monday, September 16th. BTIG Research increased their target price on Aura Biosciences from $21.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, October 18th. Cowen reissued a "buy" rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, Lifesci Capital raised Aura Biosciences to a "strong-buy" rating in a report on Monday, September 9th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $23.00.

Aura Biosciences Trading Down 3.5 %

NASDAQ AURA traded down $0.33 during trading on Monday, hitting $9.14. 485,472 shares of the company traded hands, compared to its average volume of 177,115. The business has a fifty day simple moving average of $9.82 and a 200 day simple moving average of $8.54. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38. The company has a market capitalization of $456.54 million, a P/E ratio of -5.28 and a beta of 0.33.

Insider Buying and Selling at Aura Biosciences

In related news, insider Janet Jill Hopkins sold 11,822 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the sale, the insider now owns 151,693 shares in the company, valued at approximately $1,419,846.48. This represents a 7.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Mark Plavsic sold 7,383 shares of the firm's stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now owns 121,132 shares of the company's stock, valued at $1,193,150.20. This trade represents a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 79,081 shares of company stock valued at $891,353 in the last 90 days. 5.40% of the stock is currently owned by company insiders.

Institutional Trading of Aura Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. American Century Companies Inc. acquired a new stake in shares of Aura Biosciences in the 2nd quarter valued at $119,000. American International Group Inc. increased its holdings in Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company's stock worth $138,000 after purchasing an additional 3,782 shares in the last quarter. Virtu Financial LLC acquired a new stake in Aura Biosciences in the first quarter worth $144,000. SG Americas Securities LLC acquired a new position in Aura Biosciences during the 3rd quarter worth approximately $169,000. Finally, Barclays PLC grew its position in Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after purchasing an additional 43,897 shares during the period. Institutional investors and hedge funds own 96.75% of the company's stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.